Pharmacy & Therapeutics- July 2008 - (Page 413) CONTINUING EDUCATION CREDIT blind, randomized, placebo-controlled, crossover study. Neurology 1997;48(1):103–107. Lipton, RB, Goldstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache 2005;45(4):283–292. Diener HC, Lampl C, Reimnitz P, et al. Aspirin in the treatment of acute migraine attacks. Exp Rev Neurother 2006;6(4):563–573. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine. Headache 2002;42(4):249–255. Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg in acute migraine attacks. Cephalalgia 200;20:663–667. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan, and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24(11): 947–954. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1000 mg ef fer vescent acetylsalicylic acid and sumatriptan in treating migraine symptoms. Eur Neurol 2004;52:50–56. Lipton RB, Stewart WF, Ryan RE, et al. Efficacy and safety of acetaminophen, aspirin, and caf feine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998;55:210–217. Goldstein J, Hoffman HD, Armellino JJ, et al. Treatment of severe, disabling migraine in an over-the-counter population of migraine sufferers: Results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 1999;19:684–691. Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the non-prescription combination of acetaminophen, aspirin, and caffeine: Results from three randomized, placebo-controlled studies. Clin Ther 1999;21(3):475–491. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin and caffeine in combination versus ibuprofen for acute migraine: Results from a multicenter, double-blind, randomized, parallelgroup, single-dose, placebo-controlled study. Headache 2006;6(3): 444–453. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache 2005;45: 973–982. Diener HC, Katasarva Z. Analgesic/abortive overuse and misuse in chronic daily headache. Curr Pain Headache Rep 2001;5:545–550. Mathew NT, Kurman R, Perez F. Drug-induced refractory headache: Clinical features and management. Headache 1990;13:634–638. Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double blind, placebo-controlled, doseranging study. Cephalalgia 2000;20:233–243. Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache: A randomized controlled trial. Headache 2001;41:665–679. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12(3):169–171. Lewis DW, Kellstein D, Dahl G. Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002;42(8): 780–786. Andersson PG, Hinge HH, Johansen O, et al. Double-blind study of naproxen vs. placebo in the treatment of acute migraine attacks. Cephalalgia 1989;9(1):29–32. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985;5(1)5–10. Nestvold K, Kloster R, Partinen M, et al. Treatment of acute migraine attack: Naproxen and placebo compared. Cephalalgia 1985;5(2):115–119. Massiou H, Serrurier D, Lasserre O, et al. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: A double-blind study versus placebo. Cephalalgia 1991;11:59–63. Karachalios GN, Fotiadou A, Chrisikos N, et al. Treatment of acute migraine attack with diclofenac sodium: A double-blind study. Headache 1992;32:98–100. Dahlof C, Bjorkman R. Diclofenac-K (50 mg and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993;13: 117–123. 74. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine. Neurology 2002;58:1660–1665. 75. Harden RN, Carter TD, Gilman CS, et al. Ketorolac in acute headache management. Headache 1991;31:463–464. 76. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: A comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15:31–35. 77. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992;32(6):280–282. 78. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen for the acute treatment of migraine. Headache 2005;45(8):983–991. 79. Stronks DL, Tulen JH, Bussmann HB, et al. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: A randomized, double-blind, double-dummy, crossover study. Headache 2003;43(8):845–852. 80. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006;67:497–499. 81. Pradalier A, Rancurel G, Dordain G, et al. Acute migraine attack therapy: Comparison of naproxen sodium and ergotamine tartrate compound. Cephalalgia 1985;5:107–113. 82. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: Naproxen sodium vs ergotamine plus caffeine. Headache 1988;28: 263–266. 83. Diclofenac-K and the Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison with oral sumatriptan and placebo. Cephalalgia 1999;19:232–240. 84. Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan and naproxen sodium for the treatment of acute migraine. Mayo Clin Proc 2007;82(1):61–68. 85. Peroutka S, Lyon JA, Swarbrick J, et al. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: A randomized, double-blind, crossover study. Headache 2004;44:136–141. 86. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A double blind study. Cephalalgia 1984;4:107–111. 87. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives; ethanol. In: Goodman Gilman A, Rall TW, Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics,10th ed. New York: McGrawHill; 1990:348–382. 88. Silberstein SD, McCrory DC. Butalbital in the treatment of headaches: History, pharmacology, and efficacy. Headache 2001;41: 953–967. 89. Sellers EM, Hoornweg K, Busto UE, et al. Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1999;6:18–35. 90. McLean W, Boucher EA, Brennan M, et al. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Can J Clin Pharmacol. 2000;7(4):191–197. 91. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: www. aan.com/public/practiceguidelines/03.pdf/. Accessed August 2007. 92. Capobianco DJ, Swanson JW, Dodick DW. Medication-induced (analgesic rebound) headache: Historical aspects and initial descriptions of the North American experience. Headache 2001;41: 500–502. 93. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin 1997;15(1):167–186. 94. Panconesi A, Anselmi B, Franchi G. Increased adverse effects of opiates in migraine patients. Cephalalgia 1995;15(2):159–160. 95. Boureau F, Joubert JM, Lasserre V, et al. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 1994;14:156–161. 96. Adam EI. A treatment for the acute migraine attack. J Int Med Res 1987;15:71–75. 97. Carasso RI, Yehuda S . The prevention and treatment of migraine with an analgesic combination. Br J Clin Pract 1984;38:25–27. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. Vol. 33 No. 7 • July 2008 • P&T® 413 http://www.aan.com/public/practiceguidelines/03.pdf/ http://www.aan.com/public/practiceguidelines/03.pdf/
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.